 |
Oct 15, 2009
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals |
| |
REDWOOD CITY, Calif. and PRINCETON, N.J., Oct 15, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), and Eleison Pharmaceuticals, Inc., today announced the execution of a licensing agreement granting Eleison Pharmaceuticals exclusive worldwide rights to glufosfamide. Glufosfamide is a novel small molecule...
|
|
Oct 8, 2009
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 At Melanoma Conference |
| |
REDWOOD CITY, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the Perspectives in Melanoma XIII Conference taking place in Baltimore, Maryland from...
|
|
Oct 6, 2009
Threshold Pharmaceuticals Completes $35 Million Private Equity Financing |
| |
REDWOOD CITY, Calif., Oct 6, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced the completion of its previously announced private placement of common stock and warrants. Investors in the offering purchased units consisting of one share of common stock and a warrant to purchase 0.4 of a sh...
|
|
Sep 30, 2009
Threshold Pharmaceuticals Announces Private Equity Financing of $35 Million |
| |
REDWOOD CITY, Calif., Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has entered into a securities purchase agreement with a select group of new investors that includes Federated Kaufmann Fund ("Federated"), Frazier Healthcare Ventures and Great Point Partners, LLC plus...
|
|
Sep 21, 2009
Threshold Pharmaceuticals Provides Clinical Trial Update From a Complete Phase 1/2 Clinical Trial of TH-302 in Combination With Chemotherapy |
| |
REDWOOD CITY, Calif., Sep 21, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of t...
|
|
Sep 18, 2009
Threshold Pharmaceuticals Announces a Presentation At the ECCO/ESMO Multidisciplinary Congress |
| |
REDWOOD CITY, Calif., Sep 18, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the Joint 15th Congress of the European CanCer Organisation (ECCO) and the 34th Congress of...
|
|
Aug 6, 2009
Threshold Pharmaceuticals Reports Second Quarter 2009 Financial Results |
| |
REDWOOD CITY, Calif., Aug 6, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2009.
The net loss for the second quarter of 2009 was $6.2 million compared to $4.0 million for the second quarter of 2008. Research and development ex...
|
|
Aug 4, 2009
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting |
| |
REDWOOD CITY, Calif and SCOTTSDALE, Ariz, Aug 4, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at ...
|
|
Jun 8, 2009
Threshold Pharmaceuticals ASCO Webcast Available On Company Website |
| |
REDWOOD CITY, Calif., Jun 8, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that a webcast of the Company's ASCO investor presentation is now available on the Company's website. The webcast, which was not available immediately due to technical difficulties, can be accessed on the Invest...
|
|
May 30, 2009
Threshold Pharmaceuticals Presents Encouraging Data From Clinical Trials of TH-302 for Solid Tumors |
| |
REDWOOD CITY, Calif., May 30, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology (ASCO) being held May 29 to June 2, 2009, at the ...
|
|
May 27, 2009
Threshold Pharmaceuticals Announces a Presentation At the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting |
| |
REDWOOD CITY, Calif., May 27, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 to J...
|
|
May 7, 2009
Threshold Pharmaceuticals Reports First Quarter 2009 Financial Results |
| |
REDWOOD CITY, Calif., May 7, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the first quarter ended March 31, 2009.
The net loss for the first quarter of 2009 was $6.5 million compared to $5.0 million for the first quarter of 2008. Research and development expe...
|
|
Apr 20, 2009
Threshold Pharmaceuticals Presents Positive TH-302 Preclinical Results in Three Scientific Presentations At AACR Annual Meeting |
| |
REDWOOD CITY, Calif., Apr 20, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 18 to 22, 2009, at the Colora...
|
|
Apr 14, 2009
Threshold Pharmaceuticals Announces Multiple Presentations at the 2009 American Association for Cancer Research (AACR) Annual Meeting |
| |
REDWOOD CITY, Calif., Apr 14, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple presentations on its hypoxia-activated prodrug, TH-302. The presentations will take place at the 2009 American Association for Cancer Research (AACR) Annual Meeting being held April 18 - 22, 2009, at ...
|
|
Mar 19, 2009
Threshold Pharmaceuticals Announces Going Concern Opinion |
| |
REDWOOD CITY, Calif., Mar 19, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 13, 2009, contained a going concern qualification from its...
|
|
Mar 11, 2009
Threshold Pharmaceuticals Announces Upcoming Presentation On TH-302 At the New York Academy of Sciences Hypoxia Meeting |
| |
REDWOOD CITY, Calif., Mar 11, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Charles P. Hart, Ph.D., Vice President of Biology, will present at the New York Academy of Sciences Conference on Saturday, March 14, at 4:30 p.m. Eastern Time. The conference will take place at the New Yo...
|
|
Mar 5, 2009
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results |
| |
REDWOOD CITY, Calif., Mar 5, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the fourth quarter and the year ended December 31, 2008.
The net loss for 2008 was $18.3 million compared to a net loss of $30.7 million in 2007. Total research and development expenses...
|
|
Feb 5, 2009
Threshold to Present At BIO CEO & Investor Conference On February 9 |
| |
REDWOOD CITY, Calif., Feb 5, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Barry Selick, Ph.D., Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 9, at 9:00 a.m. Eastern Time. The conference takes place at the Waldorf-Astoria Hotel in N...
|
|
Nov 19, 2008
Threshold Pharmaceuticals Appoints Dr. Jeffrey W. Bird to Board of Directors |
| |
REDWOOD CITY, Calif., Nov 19, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that the Company has appointed Dr. Jeffrey W. Bird to its board of directors. Dr. Bird will fill the seat held by Dr. Powell, a board member since 2001. Dr. Bird will serve as a member of both the Audit Committ...
|
|
Nov 13, 2008
Threshold to Present At the Lazard Capital Markets Annual Healthcare Conference |
| |
REDWOOD CITY, Calif., Nov 13, 2008 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it will present at the Lazard Capital Markets 5th Annual Healthcare Conference at the St. Regis Hotel in New York City.
Threshold's CEO, Barry Selick, Ph.D., will present at 3:40 p.m. Eastern Time on ...
|
|
|
|
